 | Brokerages Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 27 at 4:30 AM |
 | ACOR Acorda Therapeutics, Inc. Common Stock
www.nasdaq.com - May 21 at 9:41 PM |
| Short Interest in Acorda Therapeutics Inc (NASDAQ:ACOR) Increases By 8.4%
www.americanbankingnews.com - May 21 at 2:24 AM |
| Acorda Therapeutics Inc (NASDAQ:ACOR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 2:09 PM |
| Q2 2020 EPS Estimates for Acorda Therapeutics Inc Lowered by Analyst (NASDAQ:ACOR)
www.americanbankingnews.com - May 11 at 3:20 AM |
 | Acorda Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 8 at 5:34 PM |
| Acorda Therapeutics Inc (NASDAQ:ACOR) Forecasted to Post FY2022 Earnings of ($0.44) Per Share
www.americanbankingnews.com - May 8 at 5:05 PM |
| Wedbush Weighs in on Acorda Therapeutics Inc's Q1 2021 Earnings (NASDAQ:ACOR)
www.americanbankingnews.com - May 8 at 3:48 PM |
| Acorda Therapeutics (NASDAQ:ACOR) Announces Earnings Results
www.americanbankingnews.com - May 7 at 10:15 PM |
| Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
www.nasdaq.com - May 7 at 3:54 AM |
|
| Acorda Therapeutics (NASDAQ:ACOR) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 6 at 10:55 PM |
| Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Quarterly Sales of $39.34 Million
www.americanbankingnews.com - May 6 at 4:24 AM |
 | BRIEF-Acorda Reports First Quarter 2020 Financial Results And Provides Business Update
www.reuters.com - May 5 at 10:58 PM |
| Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 10:58 PM |
 | Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 5 at 10:58 PM |
| Acorda Therapeutics EPS misses by $0.10, misses on revenue
seekingalpha.com - May 5 at 5:58 PM |
| Acorda Reports First Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 5 at 5:58 PM |
| United States Metered Dose Inhaler Market (2019 to 2025) - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others
finance.yahoo.com - May 5 at 8:42 AM |
| Zacks: Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 4 at 7:36 AM |
 | Parkinson's Disease Therapeutics Market Research by Top Key Players, Applications and Forecast Report 2017 - 2025
www.marketwatch.com - April 30 at 5:48 PM |
| Global Post herpetic Neuralgia Treatment Market 2020 Analysis, Top Manufacturers, Market Size, Share, Growth Factor and Forecast to 2025
www.marketwatch.com - April 28 at 8:04 AM |
| Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
finance.yahoo.com - April 28 at 8:03 AM |
| Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
www.nasdaq.com - April 24 at 3:13 PM |
| Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 24 at 3:13 PM |
| US Sleep-Wake Disorder Market (2019 to 2025) - Featuring Aeroflow, Arena Pharmaceuticals & Acorda Therapeutics Among Others
finance.yahoo.com - April 23 at 9:32 AM |
| Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
finance.yahoo.com - April 16 at 8:08 PM |
 | The Inhaler Market in the United States to 2025 - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others - ResearchAndMarkets.com
www.businesswire.com - April 15 at 1:37 AM |
| Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
finance.yahoo.com - April 7 at 9:30 PM |
| Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
finance.yahoo.com - April 7 at 4:30 PM |
| Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
finance.yahoo.com - April 7 at 4:30 PM |
| Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
finance.yahoo.com - April 7 at 4:30 PM |
| Immunomedics (IMMU) in Focus: Stock Moves 5% Higher
finance.yahoo.com - April 3 at 3:34 PM |
| Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
www.nasdaq.com - March 31 at 9:21 PM |
| Freezing Of Gait Treatment Market Trends and Key Players: Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM,
www.marketwatch.com - March 24 at 7:22 AM |
| What Makes Acorda (ACOR) a New Buy Stock
finance.yahoo.com - March 17 at 2:19 PM |
| Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?
finance.yahoo.com - March 14 at 1:01 PM |
 | Acorda Therapeutics Inc.
www.barrons.com - March 8 at 12:26 PM |
| Acorda Therapeutics: Crisis Postponed, Inbrija Needs To Perform
seekingalpha.com - February 21 at 6:39 PM |
| Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT
finance.yahoo.com - February 17 at 5:36 PM |
| Acorda Therapeutics EPS beats by $0.26, beats on revenue
seekingalpha.com - February 14 at 2:21 PM |
| Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y
finance.yahoo.com - February 14 at 2:21 PM |
 | BRIEF-Acorda Therapeutics Posts Q4 Earnings Per Share $1.38
www.msn.com - February 13 at 12:10 PM |
| Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4
www.nasdaq.com - February 13 at 12:10 PM |
| Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call Transcript
seekingalpha.com - February 13 at 12:10 PM |
| Acorda Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 13 at 12:10 PM |
| Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4
finance.yahoo.com - February 13 at 12:10 PM |
| Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - February 13 at 12:10 PM |
| Acorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
www.businesswire.com - February 12 at 7:42 AM |
| What's in Store for Acorda (ACOR) This Earnings Season?
www.nasdaq.com - February 10 at 12:50 PM |
| Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline
finance.yahoo.com - February 6 at 5:20 PM |
